Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

G. Barosi, A. Tefferi, C. Besses, G. Birgegard, F. Cervantes, G. Finazzi, H. Gisslinger, M. Griesshammer, C. Harrison, R. Hehlmann, S. Hermouet, J. J. Kiladjian, N. Kröger, R. Mesa, M. F. Mc Mullin, A. Pardanani, F. Passamonti, J. Samuelsson, A. M. Vannucchi, A. ReiterR. T. Silver, S. Verstovsek, G. Tognoni, T. Barbui

Research output: Contribution to journal › Review article › peer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: Consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)'. Together they form a unique fingerprint.

Medicine & Life Sciences